E3 PreliminaryPreliminaryPEM not requiredCross-SectionalPeer-reviewedReviewed
Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome.
Konstantinov, K, von Mikecz, A, Buchwald, D et al. · The Journal of clinical investigation · 1996 · DOI
Quick Summary
Researchers found that about half of ME/CFS patients had antibodies (immune proteins) in their blood that attack a protein called lamin B1 found in the nucleus of cells. This suggests that ME/CFS may involve the immune system mistakenly attacking the body's own cells. This discovery provides evidence that autoimmunity—when the body's defense system malfunctions—may play a role in ME/CFS.
Why It Matters
This study offers objective laboratory evidence that autoimmunity may be involved in ME/CFS pathophysiology, supporting the biological basis of the disease and potentially opening avenues for autoimmune-targeted diagnostics or therapies. Identifying specific autoantibodies could eventually help distinguish ME/CFS from other fatigue-related conditions and stratify patients for targeted treatment approaches.
Observed Findings
- Approximately 52% of ME/CFS patient sera reacted with nuclear envelope antigens detected by immunofluorescence microscopy
- Immunoblot analysis and immunoprecipitation identified IgG autoantibodies targeting lamin B1, a nuclear envelope protein
- Autoantibodies were characterized as IgG isotype, indicating a humoral immune response
- Nuclear rim staining pattern was observed on immunofluorescence, consistent with nuclear envelope localization
Inferred Conclusions
- The presence of autoantibodies to a conserved intracellular protein (lamin B1) provides new laboratory evidence for an autoimmune component in ME/CFS
- The high prevalence of anti-nuclear envelope autoantibodies (52%) suggests autoimmunity may be a significant pathophysiologic mechanism in a substantial subset of ME/CFS patients
- The IgG isotype indicates a persistent, adaptive humoral immune response against nuclear proteins in affected individuals
Remaining Questions
- Are these lamin B1 autoantibodies present in healthy controls or other disease states, and what is their specificity and sensitivity for ME/CFS diagnosis?
- Do these autoantibodies correlate with disease severity, symptom profiles, or clinical outcomes in ME/CFS?
What This Study Does Not Prove
This study does not prove that lamin B1 autoantibodies cause ME/CFS—it demonstrates only an association. It does not establish whether these autoantibodies are a cause, consequence, or epiphenomenon of disease. The study also does not address whether these autoantibodies are present in other illnesses or healthy individuals, limiting conclusions about disease specificity.
Tags
Symptom:Fatigue
Biomarker:AutoantibodiesBlood Biomarker
Method Flag:Weak Case DefinitionNo ControlsSmall SampleExploratory Only
Metadata
- DOI
- 10.1172/JCI118990
- PMID
- 8878441
- Review status
- Editor reviewed
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.